EUVIMEDEUVIMED entdecken
Leserbrief

PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer

Kadri Altundag

Medical Oncology · 2024

DOI: 10.1007/s12032-024-02515-1 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Medical Oncology, 2024. Verfasst von Kadri Altundag. Beteiligte Einrichtung: MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphoinositide-3 Kinase InhibitorsHumansFemaleProtein Kinase InhibitorsMTOR InhibitorsAntineoplastic AgentsPhosphatidylinositol 3-Kinases

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphoinositide-3 Kinase InhibitorsMTOR protein, humanProtein Kinase InhibitorsMTOR InhibitorsAntineoplastic AgentsPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com.

Zitieren

APA

Altundag, K. (2024). PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer. Medical Oncology. https://doi.org/10.1007/s12032-024-02515-1

Vancouver

Altundag K. PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer. Medical Oncology. 2024. doi:10.1007/s12032-024-02515-1

BibTeX
@article{Altundag2024,
  author = {Altundag, Kadri},
  title = {PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer},
  journal = {Medical Oncology},
  year = {2024},
  doi = {10.1007/s12032-024-02515-1}
}
Kostenlos starten →